inhibit
viru
attach
host
cell
plasma
membran
consist
glycoprotein
glycolipid
proteoglycan
select
attach
review
envelop
virus
pose
import
health
threat
persist
mani
emerg
virus
envelop
particular
newli
emerg
virus
creat
need
develop
broadspectrum
antivir
usual
obtain
target
host
cell
factor
persist
virus
develop
effici
strategi
escap
host
immun
control
treatment
option
limit
target
host
cell
factor
essenti
viru
persist
immunebas
therapi
provid
altern
approach
review
therefor
focu
recent
develop
gener
antivir
target
host
cell
factor
immunebas
therapeut
approach
fight
infect
envelop
virus
virus
divid
nonenvelop
envelop
virus
latter
hostderiv
membran
call
envelop
cover
capsid
protect
viral
genom
membran
envelop
associ
rel
low
resist
desicc
heat
alcohol
deterg
limit
surviv
viru
particl
outsid
host
howev
carri
envelop
offer
distinct
advantag
viru
envelop
allow
viru
exit
host
cell
use
cellular
machineri
exocytosi
thu
avoid
cell
damag
prevent
immun
respons
ii
envelop
increas
packag
capac
viru
particl
allow
carri
addit
viral
protein
iii
envelop
hide
structur
restrict
capsid
antigen
circul
antibodi
iv
envelop
protein
surfac
viru
higher
structur
flexibl
capsid
protein
part
rigid
capsid
structur
thu
envelop
virus
escap
neutral
immun
respons
better
nonenvelop
counterpart
zoonot
virus
envelop
appar
variat
envelop
protein
facilit
adapt
differ
host
although
cours
addit
adapt
requir
besid
host
cell
phospholipid
protein
cellular
membran
viral
envelop
contain
viral
glycoprotein
play
major
role
bind
specif
receptor
host
cell
fusion
viral
envelop
cellular
membran
upon
viru
uptak
lead
releas
capsid
cytoplasm
wherebi
viral
genom
final
releas
initi
viru
replic
progeni
product
figur
review
focu
envelop
virus
especi
novel
treatment
approach
recent
develop
relev
envelop
virus
caus
human
diseas
list
tabl
differ
strategi
develop
fight
envelop
virus
one
hand
viral
infect
may
prevent
prophylact
vaccin
inde
success
vaccin
sever
envelop
virus
establish
tabl
hand
newli
emerg
virus
target
vaccin
vaccin
approv
yet
prevent
infect
sever
import
human
pathogen
hepat
c
viru
hcv
hiv
cytomegaloviru
cmv
epsteinbarr
viru
ebv
furthermor
despit
effect
vaccin
hepat
b
viru
hbv
million
peopl
still
chronic
infect
need
cur
therapeut
option
illustr
need
develop
new
antivir
envelop
virus
establish
novel
antivir
past
decad
proven
viral
infect
limit
even
elimin
use
inhibitori
molecul
histor
antivir
drug
discoveri
mainli
focus
viral
target
fewer
side
effect
expect
highli
specif
approach
tabl
includ
typic
viral
target
clinic
evalu
approv
antivir
disadvantag
use
distinct
viral
target
howev
risk
develop
resist
narrow
spectrum
applic
often
one
particular
viru
altern
therapeut
strategi
target
host
cell
factor
essenti
support
viral
life
cycl
use
cellular
target
help
avoid
rapid
adapt
virus
develop
drug
resist
often
allow
target
emerg
well
known
pathogen
time
therefor
target
host
cell
factor
becom
popular
antivir
drug
develop
anoth
altern
use
immunomodulatori
therapi
proven
effici
control
viral
infect
review
therefor
focu
new
develop
antivir
strategi
primarili
target
host
factor
figur
immunotherapi
target
surfac
protein
envelop
virus
figur
site
differ
envelop
virus
molecul
bind
membran
compon
compet
viru
attach
host
cell
thu
inhibit
infect
earliest
step
exampl
new
class
synthet
antilipopolysaccharid
lp
peptid
name
salp
significantli
interfer
de
novo
infect
variou
envelop
virus
vitro
hiv
herp
simplex
viru
hsv
hcv
hbv
bind
heparan
sulfat
proteoglycan
hspg
moieti
cover
cell
surfac
molecul
bind
mimic
hspg
use
inhibit
infect
distinct
envelop
virus
peptid
peptid
respiratori
syncyti
viru
rsv
lactoferrin
sever
acut
respiratori
syndrom
coronaviru
sarscov
chondroitin
sulfat
dengu
viru
chemic
sulfat
deriv
escherichia
coli
capsular
polysaccharid
cmv
product
viru
entri
requir
highaffin
receptor
bind
membran
fusion
receptor
andor
coreceptor
viru
known
block
specif
inhibitor
hiv
exampl
use
cluster
differenti
cd
chemokin
receptor
entri
receptor
hiv
fusion
inhibitor
eg
enfuvirtid
inhibitor
eg
maraviroc
alreadi
clinic
use
tabl
synthet
compound
simultan
inhibit
attach
entri
hiv
interest
candid
antivir
molecul
consist
peptid
link
dodecasaccharid
hspg
design
simultan
target
two
critic
highli
conserv
region
linkag
two
function
moieti
provid
strong
cooper
effect
result
lownanomolar
antivir
activ
toward
strain
virus
hcv
hbv
co
receptor
identifi
recent
epiderm
growth
factor
receptor
ephrin
receptor
serv
critic
host
determin
hcv
entri
regul
coreceptor
associ
membran
fusion
block
tyrosin
kinas
activ
clinic
approv
inhibitor
broadli
impair
infect
major
hcv
genotyp
known
viral
escap
variant
recent
myristoyl
peptid
deriv
ntermin
part
larg
surfac
protein
hbv
name
myrcludexb
shown
bind
sodiumtaurochol
transport
peptid
ntcp
serv
hbv
hepat
viru
hdv
receptor
myrcludex
b
effici
prevent
hbv
hdv
infect
current
evalu
clinic
trial
altern
option
requir
knowledg
viru
receptor
use
peptid
deriv
envelop
protein
viru
competit
inhibit
receptor
bind
peptid
proven
antivir
effect
dengu
viru
hsv
disrupt
viral
membran
integr
viral
membran
suscept
specif
disrupt
lack
metabol
turnov
viru
entri
requir
highaffin
receptor
bind
membran
fusion
inhibit
block
specif
receptor
b
disrupt
viral
membran
integr
arbidol
c
respect
molecul
also
modifi
intracellular
transport
pathway
hijack
viru
ezetimib
alter
lipid
metabol
inhibit
cellular
factor
involv
viral
replic
exampl
cyclophilin
e
viral
morphogenesi
glucosidas
f
decreas
product
releas
infecti
viral
particl
abbrevi
salp
synthet
antilipopolysaccharid
lp
peptid
trend
pharmacolog
scienc
septemb
vol
repair
viru
bud
host
cell
membran
although
exploit
disinfect
long
time
molecul
alter
viral
membran
evalu
new
antivir
arbidol
potent
broadspectrum
antivir
also
inhibit
membran
fusion
sever
envelop
virus
includ
influenza
viru
hcv
recent
demonstr
vitro
arbidol
interact
polar
head
phospholipid
membran
protein
motif
enrich
aromat
residu
therebi
prevent
fusion
hcv
small
molecul
intercal
lipid
membran
report
inhibit
vitro
viruscel
fusion
entri
mani
envelop
virus
includ
nipah
ebola
marburg
influenza
hiv
hcv
west
nile
viru
wnv
yellow
fever
vaccinia
virus
bind
viral
cellular
membran
gener
singlet
oxygen
membran
bilay
chang
biophys
properti
viral
membran
thu
prevent
viruscel
fusion
chang
becom
appar
cellular
membran
due
repair
cellular
lipid
biosynthesi
famili
synthet
compound
name
rigid
amphipath
fusion
inhibitor
rafi
shape
phospholipid
hydrophil
head
larger
hydrophob
tail
shown
inhibit
cell
cultur
experi
infect
sever
envelop
virus
includ
hcv
rafi
alter
neg
curvatur
viral
membran
requir
initi
fusion
like
rafi
act
membranebind
photosensit
antivir
effect
requir
activ
gener
singlet
oxygen
photosensit
viral
membran
thu
appear
interest
mechan
develop
broadspectrum
antivir
envelop
virus
virus
hijack
physiolog
transport
pathway
enter
host
cell
deliv
genom
compound
inhibit
cellular
transport
pathway
without
toxic
may
thu
use
antivir
hcv
exploit
modifi
lipid
metabol
hepatocyt
enter
hepatocyt
take
advantag
cholesterol
uptak
pathway
proven
vitro
vivo
use
ezetimib
fdaapprov
select
inhibitor
intestin
cholesterol
absorpt
circul
hcv
virion
embed
triglyceriderich
lipoprotein
includ
verylowdens
lipoprotein
vldl
lowdens
lipoprotein
ldl
therefor
refer
lipoviroparticl
inhibitor
lipoprotein
lipas
lpl
enzym
catalyz
convers
vldl
ldl
prevent
hcv
infect
vitro
well
primari
human
hepatocyt
transplant
upascid
mice
retain
viral
particl
cell
surfac
line
recent
found
ezetimib
effici
block
earli
step
hbv
life
cycl
indic
hbv
infect
also
involv
lipid
transport
pathway
virus
parasit
exploit
cellular
machineri
replic
thu
target
cellular
compon
essenti
viru
replic
anoth
promis
option
develop
new
antivir
largescal
vitro
screen
identifi
smallmolecularweight
compound
block
de
novo
pyrimidin
synthesi
act
broadspectrum
antivir
deplet
cellular
pyrimidin
pool
therebi
inhibit
clinic
evalu
c
abbrevi
il
interleukin
ntcp
sodium
taurochol
cotransport
polypeptid
bile
acid
cotransport
risc
rnainduc
silenc
complex
trend
pharmacolog
scienc
septemb
vol
number
dna
rna
virus
vitro
includ
influenza
b
virus
hcv
wnv
dengu
viru
human
adenovirus
poxvirus
hiv
howev
vivo
efficaci
toxic
interest
antivir
candid
still
need
determin
cyclophilin
famili
highli
conserv
cellular
peptidylprolyl
cistran
isomeras
involv
mani
cellular
process
protein
fold
traffick
cyclophilin
proven
essenti
hcv
replic
inhibit
cyclophilin
effici
inhibit
hcv
replic
like
prevent
cyclophilin
interact
hcv
also
act
multipl
virus
hiv
hbv
influenza
virus
sarscov
hsv
cmv
vaccinia
viru
nonimmunosuppress
inhibitor
cyclophilin
alisporivir
current
clinic
develop
hcv
therapi
review
abund
liver
mirna
shown
bind
hcv
untransl
region
utr
essenti
stabil
replic
hcv
rna
intraven
administr
lock
nucleic
acid
complementari
suppress
propag
hcv
chimpanze
chronic
infect
hcv
recent
stabil
dna
antisens
oligonucleotid
sequest
miravirsen
prove
safe
clinic
phase
ii
trial
patient
chronic
hcv
genotyp
infect
show
prolong
dosedepend
reduct
hcv
rna
level
without
evid
viral
resist
prevent
releas
matur
fulli
infecti
envelop
virus
antivir
strategi
exert
neuraminidas
inhibitor
influenza
virus
use
similar
strategi
valproic
acid
function
potent
inhibitor
sever
envelop
virus
cultur
cell
includ
wnv
vaccinia
virus
lymphocyt
choriomening
viru
lcmv
probabl
act
caus
alter
cellular
membran
composit
result
impair
infecti
particl
product
glucosidas
inhibitor
proven
antivir
efficaci
hcv
hbv
dengu
viru
alter
morphogenesi
review
glucosidas
cellular
enzym
involv
biosynthesi
glycoprotein
express
viral
surfac
essenti
virushost
interact
one
inhibitor
celgosivir
reach
clinic
phase
ii
treatment
chronic
hcv
infect
well
phase
treatment
dengu
viru
infect
amphipath
dna
polym
shown
antivir
activ
envelop
virus
includ
herp
virus
hcv
mainli
prevent
entri
among
rep
phase
iii
clinic
trial
treatment
chronic
hbv
infect
thought
interfer
biochem
process
involv
format
releas
hbv
subvir
particl
exploratori
use
rep
hepat
b
patient
without
control
clinic
trial
set
result
elimin
surfac
antigen
blood
associ
restor
capabl
immun
system
fight
infect
develop
new
antivir
strategi
block
viru
releas
also
profit
natur
occur
antivir
defens
mechan
instanc
tetherin
interferoninduc
host
factor
known
limit
envelop
viru
spread
infect
vitro
vivo
discoveri
compound
boost
surfac
express
tetherin
block
viral
antagon
would
prime
exampl
exploit
natur
cellular
antivir
defens
addit
inhibitori
molecul
discuss
passiv
activ
immun
modulatori
therapi
treat
viral
infect
current
explor
passiv
immunotherapi
compris
infus
antibodi
altern
compris
immun
modul
molecul
cytokin
immunostimulatori
oligonucleotid
activ
eg
tolllik
receptor
tlr
result
cytokin
releas
activ
immunotherapi
base
vaccin
novel
approach
adopt
transfer
immun
cell
defin
antigen
specif
focu
target
immunotherapi
directli
target
surfac
protein
envelop
virus
interfer
function
envelop
protein
viru
treatment
neutral
antibodi
prevent
virus
enter
host
cell
sever
way
bind
antibodi
protein
viral
envelop
block
bind
viru
receptor
cell
surfac
inhibit
fusion
viral
cellular
membran
addit
virusantibodi
complex
recogn
scaveng
via
fc
receptor
immun
cell
activ
complement
system
figur
passiv
immun
serumderiv
polyclon
antibodi
use
success
postexposur
prophylaxi
treatment
transplant
prevent
infect
hbv
rsv
varicella
zoster
viru
vzv
measl
viru
rabi
viru
also
nonenvelop
virus
hepat
viru
hav
entero
parvo
rotavirus
review
howev
qualiti
serumderiv
antibodi
product
vari
altern
cell
line
produc
wellcharacter
monoclon
antibodi
gener
either
fusion
b
cell
myeloma
cell
hybridoma
technolog
introduc
code
sequenc
antibodi
genet
modif
exampl
palivizumab
produc
recombin
dna
technolog
approv
prevent
rsv
infect
children
problem
prophylact
use
monoclon
antibodi
high
cost
sometim
rapid
select
viral
escap
mutant
reduc
cost
gene
therapi
use
allow
constant
secret
neutral
antibodi
hivneutr
antibodi
express
via
viral
vector
hematopoiet
stem
cell
muscl
tissu
immunoprophylaxi
hiv
infect
reduc
risk
viral
escap
highli
conserv
region
envelop
glycoprotein
target
antibodi
combin
increas
select
pressur
nevertheless
activ
prophylact
vaccin
strategi
would
still
prefer
trend
pharmacolog
scienc
septemb
vol
therapeut
applic
monoclon
antibodi
target
viral
envelop
protein
monoclon
antibodi
also
use
therapeut
set
recent
human
monoclon
antibodi
glycoprotein
b
mab
describ
treatment
hsvinfect
mice
mab
led
rapid
decreas
viru
titer
improv
surviv
mab
immobil
glycoprotein
b
trimer
inhibit
activ
fusogen
signal
henc
abrog
viral
entri
well
viral
celltocel
spread
similarli
monoclon
antibodi
hemagglutinin
fusion
peptid
influenza
viru
protect
mice
lethal
infect
treatment
monoclon
antibodi
gener
human
humab
mice
direct
hcv
envelop
glycoprotein
proven
prevent
establish
hcv
infect
chimpanze
delay
hcv
rebound
transplant
patient
also
reduc
viral
rna
undetect
level
week
chimpanze
acut
chronic
hcv
infect
sever
monoclon
antibodi
test
hiv
infect
clinic
trial
within
past
three
decad
studi
treatment
hivneutr
antibodi
interrupt
standard
antiretrovir
therapi
could
delay
viral
rebound
sever
week
review
recent
shown
administr
cocktail
hivspecif
monoclon
antibodi
led
strong
decreas
viral
load
partial
restor
immun
respons
primat
chronic
infect
siv
treatment
neutral
monoclon
antibodi
propos
mani
virus
vzv
cmv
dengu
viru
wnv
chikungunya
viru
mani
athropodborn
virus
review
howev
preclin
clinic
data
prove
therapeut
effect
evalu
side
effect
current
miss
develop
cmvspecif
monoclon
antibodi
promis
antivir
activ
preclin
model
prove
ineffect
patient
rais
strong
concern
antibodi
taken
trend
pharmacolog
scienc
septemb
vol
infect
cell
incorpor
assembl
virion
infect
even
nonpermiss
cell
via
fc
domain
virusantibodi
complex
monoclon
antibodi
target
host
factor
similar
inhibitori
molecul
antibodi
bind
host
factor
interact
viral
envelop
protein
minim
risk
develop
resist
bear
risk
toxic
host
cell
target
antibodi
lipid
domain
cell
surfac
distinct
protein
serv
viru
receptor
potenti
target
phosphatidylserin
becom
expos
cell
membran
cell
infect
hcv
vaccinia
viru
influenza
viru
initi
clinic
trial
phosphatidylserinespecif
antibodi
bavituximab
induc
reduct
hcv
rna
hcvhiv
coinfect
patient
remodel
host
cell
membran
mask
viru
receptor
drive
away
coreceptor
altern
option
inhibit
entri
regard
monoclon
anticholesterol
igg
antibodi
recogn
cluster
membran
cholesterol
use
rearrang
later
molecular
organ
co
receptor
lead
substanti
inhibit
infect
product
vitro
addit
sever
monoclon
antibodi
direct
hiv
co
receptor
develop
safeti
antivir
activ
monoclon
antibodi
proven
earli
clinic
trial
review
altern
bispecif
antibodi
deriv
consist
two
antibodi
differ
antigen
recognit
site
could
use
block
two
altern
dock
site
hiv
strain
reduc
risk
resist
mutant
occur
although
antibodybas
therapi
show
great
promis
cancer
therapi
role
antivir
therapi
establish
yet
remain
open
whether
clinic
result
justifi
high
cost
lack
function
cell
respons
toward
viral
antigen
hallmark
chronic
infect
envelop
virus
hbv
hcv
hiv
well
reactiv
cmv
ebv
immunosuppress
restor
would
help
host
control
infect
review
therefor
idea
redirect
cell
site
infect
intrigu
redirect
cell
defin
target
achiev
use
artifici
chimer
molecul
instanc
bispecif
antibodi
consist
two
antibodi
fragment
bind
viral
antigen
well
immun
cell
antigen
therebi
guid
immun
cell
infect
cell
bispecif
antibodi
first
exploit
attract
cell
influenzavirusinfect
cell
hiv
bispecif
antibodi
scfv
direct
hiv
envelop
protein
gener
approach
may
riski
use
vivo
attract
cell
infect
hiv
henc
molecul
immun
cell
might
better
suit
redirect
infect
cell
end
bispecif
antibodi
target
neutrophil
viru
particl
infect
cell
develop
success
test
cocultur
experi
trend
pharmacolog
scienc
septemb
vol
anoth
interest
option
redirect
cell
modifi
genet
express
chimer
antigen
receptor
car
car
compos
singl
chain
antibodi
fragment
bind
viral
envelop
protein
surfac
infect
cell
intracellular
signal
domain
due
necess
viral
envelop
protein
incorpor
cellular
membran
therapeut
approach
exclus
use
target
envelop
virus
car
shown
activ
specif
cell
cmv
vitro
influenza
viru
vivo
cell
express
car
bind
surfac
protein
hbv
hb
effici
kill
infect
primari
hepatocyt
control
viral
replic
transgen
mice
hbv
unlik
virus
stagedepend
protein
express
socal
earli
late
shift
would
allow
target
limit
time
span
hbvinfect
cell
constantli
produc
hb
even
viru
replic
control
therefor
target
hb
immunotherapi
repres
promis
approach
cure
hepat
b
antivir
cell
respons
might
also
induc
therapeut
vaccin
promin
exampl
recent
experi
cmvbase
vaccin
vector
confer
sustain
control
even
clearanc
siv
macaqu
use
model
hiv
infect
virusinfect
cell
also
target
indirectli
boost
host
immun
respons
form
interferon
concept
part
standard
care
treatment
chronic
viral
hepat
current
sever
new
immun
modulatori
substanc
test
interferon
l
initi
prove
least
effect
treatment
chronic
hepat
c
fewer
side
effect
emerg
studi
zeuzem
et
al
ilc
oral
present
clinic
develop
halt
allor
treatment
regimen
hepat
c
becom
avail
antibodi
direct
program
cell
death
protein
ligand
socal
immun
checkpoint
inhibitor
revert
exhaust
phenotyp
virusspecif
cell
tlr
agonist
induc
antivir
innat
immun
respons
promis
candid
immunotherapi
viral
infect
tabl
antibodi
direct
viral
envelop
protein
cellular
entri
receptor
link
immun
modul
antivir
molecul
discuss
first
part
review
exampl
antibodi
specif
glycoprotein
herp
virus
fuse
toxin
induc
lysi
infect
cell
immunoconjug
could
use
target
cell
infect
envelop
virus
allow
effici
deliveri
antivir
drug
immunomodul
site
infect
thu
reduc
site
effect
review
focus
novel
therapeut
approach
envelop
virus
includ
import
human
pathogen
major
advanc
relat
antivir
strategi
continu
develop
success
recent
avail
hiv
hcv
therapi
demonstr
effici
therapi
develop
suitabl
infect
system
avail
research
effort
combin
drugdevelop
effort
within
pharmaceut
industri
review
emphas
need
increas
research
development
activ
fight
import
human
pathogen
virus
target
antivir
strategi
viral
infect
may
prevent
prophylact
vaccin
vaccin
avail
howev
despit
vaccin
effort
signific
number
human
still
suffer
infect
eg
case
hepat
b
antivir
treatment
need
establish
directli
act
antivir
target
viral
enzym
protein
proven
abl
limit
orif
viru
establish
persist
reservoir
even
elimin
viral
infect
disadvantag
target
distinct
viral
protein
enzym
howev
high
risk
resist
develop
narrow
spectrum
applic
often
one
particular
viru
altern
therapeut
strategi
therefor
often
aim
target
host
cell
factor
essenti
support
viral
life
cycl
avoid
rapid
develop
resist
also
allow
target
emerg
pathogen
use
similar
infect
strategi
known
virus
especi
chronic
persist
viral
infect
immun
therapi
provid
attract
altern
also
proven
effici
control
viral
infect
yet
broadli
exploit
